Mascarenhas, J., Kosiorek, H., Prchal, J., Yacoub, A., Berenzon, D., Baer, M. R., … Hoffman, R. (2019). A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia, 33(12), 2974–2978. https://doi.org/10.1038/s41375-019-0524-7

Mascarenhas, J., H. Kosiorek, J. Prchal, A. Yacoub, D. Berenzon, M. R. Baer, E. Ritchie, et al. “A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.” Leukemia 33, no. 12 (December 2019): 2974–78. https://doi.org/10.1038/s41375-019-0524-7.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, et al. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019 Dec;33(12):2974–8.

Mascarenhas, J., et al. “A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis.” Leukemia, vol. 33, no. 12, Dec. 2019, pp. 2974–78. Pubmed, doi:10.1038/s41375-019-0524-7.

Mascarenhas J, Kosiorek H, Prchal J, Yacoub A, Berenzon D, Baer MR, Ritchie E, Silver RT, Kessler C, Winton E, Finazzi MC, Rambaldi A, Vannucchi AM, Leibowitz D, Rondelli D, Arcasoy MO, Catchatourian R, Vadakara J, Rosti V, Hexner E, Kremyanskaya M, Sandy L, Tripodi J, Najfeld V, Farnoud N, Salama ME, Weinberg RS, Rampal R, Goldberg JD, Mesa R, Dueck AC, Hoffman R. A prospective evaluation of pegylated interferon alfa-2a therapy in patients with polycythemia vera and essential thrombocythemia with a prior splanchnic vein thrombosis. Leukemia. 2019 Dec;33(12):2974–2978.